Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 6/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4453781 | 0.74 | GRM2 (0.46) | GRM2PGRTNKS2F2RTAAR1 | |
| SCHEMBL4450106 | 0.73 | BRD4 (0.35) | GRM2 | |
| SCHEMBL4458127 | 0.69 | GRM2 (0.38) | GRM2BACE1PDE3BPDE3A | |
| SCHEMBL4480095 | 0.68 | CTRC (0.35) | GRM2 | |
| SCHEMBL4454488 | 0.66 | KDM4E (0.34) | GRM2BACE1 | |
| SCHEMBL15743932 | 0.65 | FADS1 (0.42) | GRM2 | |
| SCHEMBL4444398 | 0.65 | PDE3B (0.38) | GRM2PGRPDE3BPDE3A | |
| SCHEMBL9926818 | 0.65 | TSHR (0.46) | — | |
| SCHEMBL257773 | 0.63 | TNKS2 (0.56) | PGRTNKS2TAAR1ESR2 | |
| SCHEMBL3869130 | 0.63 | PGR (0.72) | GRM2PGRTNKS2F2RPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137577-A1 | HETEROCYCLIC COMPOUNDS | CYP2D6, ABCG2, CYP2B6 | GRM2 4432/4885PGR 855/4885TNKS2 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.